315 related articles for article (PubMed ID: 36002184)
1. Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S; Chevalier MF; Benmerzoug S; Cesson V; Schneider AK; Rodrigues-Dias SC; Dartiguenave F; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002184
[No Abstract] [Full Text] [Related]
2. Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures.
Varesano S; Zocchi MR; Poggi A
Front Immunol; 2018; 9():998. PubMed ID: 29867975
[TBL] [Abstract][Full Text] [Related]
3. Aberrant phenotypes of circulating γδ-T cells may be involved in the onset of systemic lupus erythematosus.
Yuan S; Wang C; Zeng Y; Li J; Li W; He Z; Ye J; Li F; Chen Y; Lin X; Xu Y; Yu N; Cai X
Lupus; 2024 May; 33(6):587-597. PubMed ID: 38506324
[TBL] [Abstract][Full Text] [Related]
4. γδ T Cells Support Antigen-Specific αβ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer.
Ji N; Mukherjee N; Shu ZJ; Reyes RM; Meeks JJ; McConkey DJ; Gelfond JA; Curiel TJ; Svatek RS
Cancer Immunol Res; 2021 Dec; 9(12):1491-1503. PubMed ID: 34607803
[TBL] [Abstract][Full Text] [Related]
5. Exhausted intratumoral Vδ2
Rancan C; Arias-Badia M; Dogra P; Chen B; Aran D; Yang H; Luong D; Ilano A; Li J; Chang H; Kwek SS; Zhang L; Lanier LL; Meng MV; Farber DL; Fong L
Nat Immunol; 2023 Apr; 24(4):612-624. PubMed ID: 36928415
[TBL] [Abstract][Full Text] [Related]
6. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
[TBL] [Abstract][Full Text] [Related]
7. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
8. Vδ1 Effector and Vδ2 γδ T-Cell Subsets Shift in Frequency and Are Linked to Plasma Inflammatory Markers During Antiretroviral Therapy-Suppressed HIV Infection.
Pihl RMF; Smith-Mahoney EL; Olson A; Yuen RR; Asundi A; Lin N; Belkina AC; Snyder-Cappione JE
J Infect Dis; 2024 May; 229(5):1317-1327. PubMed ID: 38390982
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study.
Ji N; Mukherjee N; Reyes RM; Gelfond J; Javors M; Meeks JJ; McConkey DJ; Shu ZJ; Ramamurthy C; Dennett R; Curiel TJ; Svatek RS
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653802
[TBL] [Abstract][Full Text] [Related]
10. Long-term use of interferon-β in multiple sclerosis increases Vδ1
Maimaitijiang G; Watanabe M; Shinoda K; Isobe N; Nakamura Y; Masaki K; Matsushita T; Yoshikai Y; Kira JI
J Neuroinflammation; 2019 Sep; 16(1):179. PubMed ID: 31519178
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and functional heterogeneity of peripheral γδ T cells in pulmonary TB and HIV patients in Addis Ababa, Ethiopia.
Negash M; Tsegaye A; Wassie L; Howe R
BMC Infect Dis; 2018 Sep; 18(1):464. PubMed ID: 30219039
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic changes of γδ T cells in
Nana CMM; Tchakounté BDK; Bitye BMZ; Fogang B; Zangue BKT; Seumko'o RMN; Nana BC; Leke RGF; Djontu JC; Argüello RJ; Ayong L; Megnekou R
Front Immunol; 2024; 15():1385380. PubMed ID: 38827744
[TBL] [Abstract][Full Text] [Related]
13. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.
Wistuba-Hamprecht K; Martens A; Haehnel K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Demuth I; Steinhagen-Thiessen E; Larbi A; Schilling B; Schadendorf D; Wolchok JD; Blank CU; Pawelec G; Garbe C; Weide B
Eur J Cancer; 2016 Sep; 64():116-26. PubMed ID: 27400322
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Vδ1(+) and Vδ2(+) γδ T cell subsets in acute liver allograft rejection.
Yu X; Liu Z; Wang Y; Wang H; Zhang M; Sun Y; Su H; Jin L; Wang F; Shi M
Transpl Immunol; 2013 Dec; 29(1-4):118-22. PubMed ID: 24029467
[TBL] [Abstract][Full Text] [Related]
15. Blocking of EphA2 on Endometrial Tumor Cells Reduces Susceptibility to Vδ1 Gamma-Delta T-Cell-Mediated Killing.
Hudecek R; Kohlova B; Siskova I; Piskacek M; Knight A
Front Immunol; 2021; 12():752646. PubMed ID: 34691070
[TBL] [Abstract][Full Text] [Related]
16. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin.
Maeurer MJ; Martin D; Walter W; Liu K; Zitvogel L; Halusczcak K; Rabinowich H; Duquesnoy R; Storkus W; Lotze MT
J Exp Med; 1996 Apr; 183(4):1681-96. PubMed ID: 8666926
[TBL] [Abstract][Full Text] [Related]
17. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccination influences subtypes of γδ-T cells during pregnancy.
Wang L; Li J; Jiang S; Li Y; Guo R; Chen Y; Chen Y; Yu H; Qiao Q; Zhan M; Yin Z; Xiang Z; Xu C; Xu Y
Front Immunol; 2022; 13():900556. PubMed ID: 36311780
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy accelerates immune-senescence and functional impairments of Vδ2
Bruni E; Cazzetta V; Donadon M; Cimino M; Torzilli G; Spata G; Leonardi G; Dieli F; Mikulak J; Mavilio D
J Immunother Cancer; 2019 Dec; 7(1):347. PubMed ID: 31829255
[TBL] [Abstract][Full Text] [Related]
20. Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.
Knight A; Piskacek M; Jurajda M; Prochazkova J; Racil Z; Zackova D; Mayer J
Cancer Immunol Immunother; 2023 May; 72(5):1209-1224. PubMed ID: 36376516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
